Meeting
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
Authors
Brett A. Schroeder
Virginia Mason Medical Center, Seattle, WA
Brett A. Schroeder , Margaret T. Mandelson , Vincent J. Picozzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4125)
DOI
10.1200/JCO.2021.39.15_suppl.4125
Abstract #
4125
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first line metastatic pancreatic cancer (MPC): Updated results.
First Author: Vincent J. Picozzi
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe
Poster
2014 ASCO Annual Meeting
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
First Author: Thomas Adam Abrams